Fig. 3

The combination of DCA and PX-478 leads to increased ROS activity in HT-29 cells. Figure 3 shows HPLC analysis results and cell counts for HT-29 cells. a: HPLC results for the proportion of arachidonic acid to its oxygenated derivatives 10−/15-HETE for drug treatment compared to the control treatment are presented. Cells were treated with either the EC₅₀ dose of DCA, the EC₅₀ dose of PX-478 or the combination. Cells treated with PX-478 alone and with the combination of DCA and PX-478 showed a significant increase in the oxidation ratio compared to that in control cells, although the difference between the combination and PX-478 was noticeable but not significant. b: The cell count as a percentage of the control cell count is presented. Treatment with the single compounds DCA and PX-478 led to significant reductions of 65 and 61%, respectively. Only 15% of the control cells remained after the combination treatment. Significant differences from the control are marked with an asterisk (*), while significant differences from both the control and each single compound are marked with two asterisks (**). c: The profound effects of DCA, PX-478 and DCA + PX-478 on cell confluency are shown. All cells were imaged at 40× magnification with a Nikon D90